Table of contents

  • Renal Cell Carcinoma - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (US) 2020

Author(s): Vandana, M.Pharm

Vandana is a Research Associate in the oncology team at Decision Resources Group. Her current work is focused on performing market research in several oncology indications across the major pharmaceutical markets.

Prior to joining DRG, she worked as a Business Analyst (Digital marketing) at Iquanti, Bangalore. She has also previously worked as Analyst in WNS, Noida, India. She has worked on multiple client projects involving competitive intelligence, forecasting, pipeline analysis, keywords research and product/company profiling. She has earned her Master's in Pharmacology from DIPSAR, New Delhi, India.


Related Reports

Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (US)

The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and angi...

View Details

Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across the major mature pharmace...

View Details